Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

Click for more information

8.43%

$1.35 mesoblast limited

Cell Therapy News/Articles, page-15057

First 15057 Last

Share
Profile

Follow
Sector

35,472 Posts.

2863

26/01/23

15:24

Post #: 65894507
Share

Originally posted by madamswer: ↑

"The FDA process is pretty well established from decades of evaluating many different types of treatments and therapies and devices. The problem is that MSB's treatment claims have been consistently watered down and changed while launching new phase 3 trials even though the phase 2 trial failed..."

Sensational.

While I some years ago saw the sense in no longer reading the inane dross posted by your co-respondent, I couldn't help noticing from your response that the lame "FDA-ate-MSB's-homework" line of excuse still gets trotted out year after year.

That's despite the claim after the last US federal election that, whereas the last administration was negligent in failing to doing so, the new government were going to bring about changes at the FDA that would cause the folk at the FDA to see the error of their ways when it came to MSB.

Two years later, and the dastardly FDA continues to refuse to come up to the standard expected of it by certain MSB shareholders.

As for MSB getting to the point of self-sustaining commercialisation, well....

.

Expand

Poor Old Dolce.....12 years at it.
and its still everybody else's fault.....FDA, shorters, downrampers, the black widow....LOL

Delusional entertainment

Last edited by Sector: 26/01/23

MSB Price at posting: 96.0¢ Sentiment: Buy Disclosure: Not Held
5 Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

FFM

Firefly positioned for copper growth in Canada ahead of resource update

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3,192 more messages in this thread...

First 15057 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.35		Change 0.105(8.43%)		Mkt cap ! $1.541B

Open	High	Low	Value	Volume
$1.27	$1.40	$1.27	$16.46M	12.22M

Buyers (Bids)

No.	Vol.	Price($)
6	59739	$1.35

Sellers (Offers)

Price($)	Vol.	No.
$1.36	5000	1

View Market Depth

No.	Vol.	Price($)
6	59739	1.350
4	14088	1.345
2	47555	1.340
3	94633	1.335
4	66925	1.330

Price($)	Vol.	No.
1.360	5000	1
1.365	56441	4
1.370	140305	9
1.375	37954	3
1.380	113521	16

Last trade - 16.10pm 03/10/2024 (20 minute delay)

MSB (ASX) Chart